Released a discussion draft to modernize clinical trials and accelerate cures, with a goal of making the U.S. clinical research system faster and more integrated into care.
Proposes modernizing clinical trials to speed up the clinical research system and integrate it more closely with care delivery.
Dr. Makary began his FDA tenure with the promise of upholding principles of gold standard science, radical transparency, and common sense.
Auchincloss criticized FDA leadership and the White House for politicizing drug approvals and implied support for restoring science-based clinical and regulatory decision-making, but did not make a new personal commitment beyond existing clinical research modernization.
"We want to then release final legislative text, mark it up, demonstrate committee support this year and that way when we're negotiating PDUFA next year, it can catch a ride,"
Auchincloss said he wants to advance and ready a bipartisan clinical trial reform package for the next PDUFA reauthorization, including final text, markup, and committee support this year.
"the goal is to finalize the proposal this fall after stakeholder feedback and attach the package to the next FDA user fee reauthorization bill"
Auchincloss said he aims to finalize a bipartisan clinical trial reform proposal this fall and attach it to the next FDA user fee reauthorization bill.
“I think the theory behind that is clinical trial modernization,” Auchincloss said, and the article says he plans to solicit stakeholder feedback by July 1, release a final version in the fall, and attach the package to the next FDA user fee reauthorization bill.
Auchincloss is advancing a proposal to modernize clinical trials, with a stated plan to finalize it in the fall and move it through the next FDA user fee bill.
Rep. Jake Auchincloss, D-MA, said the goal is to finalize the proposal this fall after stakeholder feedback and attach the package to the next FDA user fee bill.
Auchincloss committed to finalizing the clinical trials reform proposal this fall and moving it through the next FDA user fee bill.
Rep. Jake Auchincloss posted a new discussion draft saying the U.S. clinical research enterprise is fragmented and difficult to integrate into care sites, and that the draft aims to modernize and improve the clinical trials process for faster and more accessible trials.
Concrete legislative draft released in the lookback window advances the stated goal of modernizing and integrating clinical trials into care, but it is still only a draft rather than enacted law or completed committee action.
Auchincloss said he wants to release final legislative text, mark it up, and demonstrate committee support this year so the package can move with the next PDUFA reauthorization; the draft would create a Cures in Care Initiative to run more trials through routine care settings.
This shows active follow-through and a concrete legislative strategy, but not delivery of the underlying reform yet; the promise remains in progress and unresolved at the lawmaking stage.
The congressman released a discussion draft saying the U.S. clinical research enterprise is fragmented and that the proposal is intended to modernize and improve clinical trials so they are faster and more accessible.
Official release shows a concrete same-term step toward modernizing clinical trials, but only at the draft stage rather than enacted or implemented reform.
Auchincloss said he wants final legislative text, markup, and committee support this year so the clinical trial reform package can move with the next PDUFA reauthorization; the draft would create a Cures in Care Initiative to shift more trials into routine care settings.
He is pursuing a concrete legislative pathway and naming implementation vehicles, but the reform remains prospective and unenacted.
The official release says America's clinical research enterprise is fragmented and difficult to integrate into care sites, and that the discussion draft aims to modernize and improve clinical trials for faster and more accessible U.S. trials.
Auchincloss took a concrete same-term step aligned with the promise by releasing a clinical-trial modernization discussion draft, but it remained a draft rather than enacted or implemented reform.
The PDF is labeled DRAFT and says the proposal would modernize clinical development through clinical trial platforms that shift research from a separate, fragmented system into a core function of U.S. health care.
The draft text closely matches the promise's substance, including faster clinical development and integration into care, but the DRAFT label shows it had not yet become law or an implemented program.
The draft would create a Cures in Care Initiative to embed clinical trials into routine health care, assign FDA CDER's Center for Clinical Trial Innovation as a coordinating entity, and establish reusable point-of-care clinical trial platform networks.
The proposal contains specific mechanisms for integrating clinical research into care, supporting an effort badge, but these mechanisms were only proposed in draft form.
The draft says near-term legislation would launch regional and national pilot trial platforms, use CMS/ONC interoperability standards for real-world clinical research, and modernize Phase 1 testing to reduce costs and accelerate clinical launches.
The draft lays out detailed modernization goals, but they are prospective legislative aims rather than fulfilled policy outcomes as of July 2, 2026.
The release invited feedback on the proposal and set a June 30 feedback deadline, indicating the measure was still in discussion-draft and comment stage.
Because the official release sought comments rather than announcing introduction, passage, enactment, or agency implementation, it supports a finding that the promise had not been delivered by the as-of date.
Auchincloss said he wanted to release final legislative text, mark it up, and show committee support in 2026 so the package could move with the next PDUFA reauthorization expected in 2027.
The article confirms a concrete legislative strategy but also shows the reform was still prospective, with final text, markup, committee support, and a legislative vehicle still ahead.
The reported proposal would create a Cures in Care Initiative, designate FDA's clinical-trial innovation hub as the lead HHS entity, develop point-of-care trial networks, clarify use of alternatives to animal testing, and pilot oversight changes for lower-risk Phase 1 trials.
The package was substantively relevant to the promise and advanced enough to have detailed provisions, but the report describes a proposal, not completed federal modernization.
The official page identifies itself as 'All Sponsored And Cosponsored Legislation' and lists recent 119th Congress items updated through May 26, 2026; the visible recent list does not include a Cures in Care or clinical-trial modernization bill following the May 14 draft release.
The official legislation tracker does not show the draft converted into a recent introduced bill by the latest visible update, reinforcing that the promise remained undelivered as of the assessment date.
Auchincloss materially advanced the promise in the same federal House term by releasing a detailed May 2026 discussion draft aimed at faster, more integrated clinical trials, including a Cures in Care Initiative and point-of-care trial networks. But the evidence shows the proposal was still a draft seeking feedback, with final legislative text, markup, committee support, passage, and implementation still prospective. There is no evidence it had been introduced, enacted, or implemented by July 2, 2026, so the promised modernization was not delivered despite a serious effort.
provider codex_cli · model gpt-5.5 · confidence 94%
neversame_termA for effort
Jake Auchincloss made a concrete same-term legislative push by releasing a discussion draft and seeking markup, committee support, and PDUFA vehicle alignment for clinical trial reform. But the evidence shows only a draft and prospective strategy, not enacted law or implemented modernization, so the promise was not fulfilled.
provider codex_cli · model gpt-5.4-mini · confidence 97%
partialsame_termA for effort
Auchincloss has materially advanced the promise in federal office by releasing a discussion draft and pursuing a legislative path to integrate clinical trials into routine care and modernize the U.S. clinical research system. However, the cited evidence shows the proposal remains at the draft and strategy stage, with no enacted law, final rule, funded implemented program, or completed federal reform delivering the promised systemwide outcome. This warrants partial credit for concrete same-term action, not full delivery.
provider codex_cli · model gpt-5.5 · confidence 92%